SUSTANON 250mg/ml Testosterone Propionate 30mg/ml Testosterone Isocaproate 60mg/ml Testosterone Decanoate 100mg/ml Testosterone Phenylpropionate 60mg/ml

Molecular Formula:

C19H28O2

Molecular Weight:

288.431 g/mol

Structure:

DESCRIPTION

Testosterone Compound is an androgenic preparation for intramuscular administration containing four different esters of the natural hormone testosterone.

INDICATIONS

Testosterone replacement therapy in male hypogonadal disorders, for example:

After castration Eunuchoidism Hypopituitarism

CONTRAINDICATIONS

Known or suspected mammary or prostatic carcinoma in the male. This medicine is not intended for use in female patients.

This preparation is also contraindicated in patients with a history of hypersensitivity to any of its components.

• Woman who are or may become pregnant
• Benign prostatic hyperplasia with obstruction
• Undiagnosed genital bleeding
• Severe kidney and heart failure

WARNINGS

Middle-aged and elderly males with angina pectoris or other severe circulatory disease should receive androgen treatment only under very careful supervision.

DRUG INTERACTIONS

When administered concurrently, the following drugs may interact with androgens, have been reported to decrease the anticoagulant requirement.

Patients receiving oral anticoagulant therapy require close monitoring especially when androgens are started or stopped.

• Antidiabetic agents oral or
• Cyclosporine
• Hepatotoxic medications,other
• Human growth hormone (Somatropin)

DOSAGE AND ADMINISTRATION

In general, dosage should be adjusted according to the response of the individual pa- tient. Usually, one injection of 1 ml per four weeks is adequate.

SUSTANON should be administered by deep intramuscular injection.

SIDE EFFECTS AND SPECIAL PRECAUTIONS

The following adverse reactions have been associated with androgen therapy: Priapism and other signs of excessive sexual stimulation.

In prepubertal boys: precocious sexual development, an increased frequency of erections, phallic enlargement and premature epiphyseal closure.

• Oligospermia and decreased ejaculatory
• Water and salt retention

• Skin : virilism
• Nervous: insomnia, headache, depression
• Liver : cholestatic hepatitis
• Kidney : bladder irritability or urinary tract infection

PRECAUTIONS

If an androgen-associated adverse reaction occurs, treatment should be interrupted and, after disappearance of the symptoms, be resumed at a lower dosage. Patients with latent or overt cardiac failure, renal dysfunction, hypertension, epilepsy or migraine (or a history of these conditions) should be monitored, since androgens may occasionally induce salt and fluid retention. Androgens should be used cautiously in pre-pubertal boys to avoid premature epiphyseal closure or precocious sexual development. A decrease in protein bound iodine (PBI) may occur,but this has no clinical significance. Treatment of male patients over the age of approximately 50 years with androgens should be preced- ed by a thorough examination of prostate and baseline measurement of prostate-specif- ic antigen serum concentration.

PATIENT MONITORING

• Bone age determinations
• Cholesterol and/or HDL and LDL
• Hemoglobin and Hematocrit determinations
• Hepatic function determinations
• Prostatic acid phosphatase and prostatic specific antigen
• Testosterone, total, serum

For treatment of breast carcinoma

Alkaline phosphatase, serum values and physical examination and x-rays of known or suspected metastases

For gender change androgen therapy

LH, ALT [SGPT]

PACKAGING

250 mg/ml, 1 ml cartridges

STORAGE

Store in a cool dry place (< 25ºC). Protect from light. Warming and rotating the vial between the palms of the hands will redissolve any crystals that may have been formed during storage at low temperatures.